New copycat cancer drug faces keytruda in Head-to-Head test

NCT ID NCT06551064

Ongoing Disease control Sponsor: Formycon AG Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a new biosimilar drug called FYB206 behaves similarly in the body to the established cancer drug Keytruda. The trial involves 96 patients with stage IIB/IIC or III melanoma who have had their cancer completely removed by surgery. Researchers want to see if the new drug has similar absorption and effects as Keytruda when used to help prevent the cancer from returning.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Formycon Investigative Site

Sarajevo, Bosnia and Herzegovina
Formycon Investigative Site

Sofia, Bulgaria
Formycon Investigative Site

Tartu, Estonia
Formycon Investigative Site

Batumi, Georgia
Formycon Investigative Site

Kutaisi, Georgia
Formycon Investigative Site

Tbilisi, Georgia
Formycon Investigative Site

Kaunas, Lithuania
Formycon Investigative Site

Chisinau, Moldova
Formycon Investigative Site

Skopje, North Macedonia
Formycon Investigative Site

Krakow, Poland
Formycon Investigative Site

Lodz, Poland
Formycon Investigative Site

Bucharest, Romania
Formycon Investigative Site

Cluj-Napoca, Romania
Formycon Investigative Site

Belgrade, Serbia
Formycon Investigative Site

Kragujevac, Serbia
Formycon Investigative Site

Niš, Serbia
Formycon Investigative Site

Kyiv, Ukraine

Conditions

Explore the condition pages connected to this study.

MELANOMA STAGE III MELANOMA, STAGE II